World Health Organization Raises Alert Over Severe Lack of Weight-Loss Medications
Under a tenth of individuals eligible to benefit from obesity jabs including Wegovy have access to them, caution the World Health Organization as it releases its first guidance on the therapies.
Considering more than one billion individuals worldwide now obese, it is advocating for more widespread and fairer access to this class of drugs.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that excess weight is a long-term condition that can be addressed with holistic and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the treatments that can aid individuals in losing considerable weight, explains the body.
Skinny Jab Scarcity
Despite the present most optimistic outlook, the supply of such drugs might only reach approximately 100 million people – fewer than 10% of eligible patients, per the WHO.
The advice encourages countries and companies to widen availability, by measures such as licensing agreements.
A patent on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Jabs Operate
The injections mimick a biological compound to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake.
Individuals usually see weight reduction within a few weeks of commencing the regular doses.
Evidence suggests patients may see weight return within a year of halting the treatment, as their normal hunger return.
To be above a healthy weight increases your risk for developing health problems, including diabetes, heart disease, stroke, and some cancers.
Excess weight affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the health agency.
